problems with glp-1 drugs Your guide to side effects GLP-1 Receptor Agonist Shortage: Challenges

Arizona OPEN ACCESS PUBLISHED:30 October 2024 CITATION:Chakkera, S

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase depression risk, a new review concludes.

Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes

Contains clinically studied ingredients: METABOLAID, ERIOMIN, and Chromium